With increasing cancer prevalence, the Minimal Residual Disease Testing Market is poised for substantial growth over the next decade. Advanced molecular diagnostics, 
Europe and North America continue to lead in technological adoption, whereas emerging economies show promising growth potential due to rising healthcare investments. Continuous R&D and regulatory approvals are projected to expand the Minimal Residual Disease Testing Market growth trajectory globally, ensuring sustained innovation in early cancer diagnostics.

FAQ:
Q1: What factors drive the market forecast?
A1: Rising cancer incidence, technological advancements, and supportive healthcare policies.

Q2: How are emerging economies impacting the market?
A2: Increased investments and awareness are leading to higher adoption of diagnostic tests.